{"id":"ulunar","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["LABA/LAMA"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ulunar","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:32:27.995965+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:32:41.785837+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:32:34.372945+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ulunar","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:32:34.715556+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Ulunar, marketed by Fundacio Privada Mon Clinic Barcelona, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current marketed status, providing a stable revenue stream for the company. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","ecosystem":[],"_scrapedAt":"2026-03-27T23:37:08.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:32:41.785903+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"NAUSEA"},{"count":10,"reaction":"MELAENA"},{"count":7,"reaction":"ABDOMINAL PAIN"},{"count":6,"reaction":"ATRIAL FIBRILLATION"},{"count":6,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":6,"reaction":"TACHYCARDIA"},{"count":5,"reaction":"DYSPNOEA"},{"count":4,"reaction":"ABDOMINAL PAIN UPPER"},{"count":4,"reaction":"HAEMATEMESIS"},{"count":4,"reaction":"PALLOR"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ulunar","genericName":"Ulunar","companyName":"Fundacio Privada Mon Clinic Barcelona","companyId":"fundacio-privada-mon-clinic-barcelona","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:32:41.785903+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}